Bank of Hawaii Has $3.99 Million Holdings in Danaher Co. (NYSE:DHR)

Bank of Hawaii increased its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 23.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,348 shares of the conglomerate's stock after acquiring an additional 2,763 shares during the quarter. Bank of Hawaii's holdings in Danaher were worth $3,989,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of DHR. nVerses Capital LLC acquired a new position in shares of Danaher during the second quarter valued at $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher in the second quarter valued at $25,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher during the 3rd quarter valued at $40,000. Darwin Wealth Management LLC acquired a new position in shares of Danaher in the 3rd quarter worth $55,000. Finally, MFA Wealth Advisors LLC purchased a new stake in shares of Danaher during the second quarter valued at $51,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Up 0.7 %

Danaher stock traded up $1.62 during mid-day trading on Monday, hitting $237.46. 994,383 shares of the company's stock were exchanged, compared to its average volume of 2,753,543. The stock has a market cap of $171.51 billion, a P/E ratio of 45.01, a P/E/G ratio of 4.34 and a beta of 0.85. The stock has a 50 day moving average of $258.15 and a two-hundred day moving average of $260.03. Danaher Co. has a 1-year low of $215.68 and a 1-year high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the company earned $2.02 EPS. The company's revenue for the quarter was up 3.1% on a year-over-year basis. As a group, analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher's payout ratio is presently 20.61%.

Analysts Set New Price Targets

A number of analysts have commented on DHR shares. Robert W. Baird reduced their price objective on shares of Danaher from $278.00 to $277.00 and set an "outperform" rating for the company in a research note on Wednesday, October 23rd. TD Cowen lifted their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a "buy" rating in a research report on Wednesday, October 23rd. Raymond James reduced their target price on Danaher from $310.00 to $300.00 and set an "outperform" rating for the company in a report on Wednesday, October 23rd. Wells Fargo & Company initiated coverage on Danaher in a research report on Tuesday, August 27th. They set an "equal weight" rating and a $280.00 price target on the stock. Finally, Barclays reduced their price objective on Danaher from $285.00 to $275.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.